Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma

NCT01124734 is registered in ClinicalTrials.gov with Milton S. Hershey Medical Center as lead sponsor.

NCT NCT01124734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01124734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma
Lead sponsor
Milton S. Hershey Medical Center
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
July 1, 2018
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma